New capsule aims to revive old antibiotic for gut infection
NCT ID NCT07251127
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new delayed-release metronidazole capsule designed to release the drug directly in the colon, where C. diff bacteria live. 18 healthy adults will receive a single dose of either the new capsule or the standard tablet to compare how much drug reaches the colon versus the bloodstream. The goal is to improve treatment of C. diff infections while reducing side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Metronidazole delayed-release capsules
What this could lead to
If successful, this new capsule could deliver more drug to the colon, potentially making metronidazole a more effective and safer first-line treatment for C. diff infections.
What could go wrong
This is a very early Phase 1 study in only 18 healthy people, so it cannot prove the drug works for patients. The new capsule may not improve outcomes or could cause unexpected side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLOSTRIDIUM DIFFICILE INFECTION (CDI) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Veeda Lifesciences
Ahmedabad, Gujarat, India